BDRX Biodexa Pharmaceuticals PLC: Forward Price-to-Revenue Multiple

Corporate emblem and logo of Biodexa Pharmaceuticals (BDRX)

Biodexa Pharmaceuticals (BDRX) focuses on the therapy of rare brain tumors, occupying a niche in neuro-oncology. This forward P/S chart allows for the business valuation to be stripped of market noise, with the 6.40 mark characterizing this parameter. Patented drug delivery systems ensure the company's stability, while the current development stage is dedicated to the commercialization of the portfolio following a series of major mergers.

Biodexa Pharma - BDRX Forward P/S Multiple (period 04/28/2023 - 04/13/2025)

Financial and market metric breakdowns for biodexapharma.com (BDRX)

- current price and projected stock value:
Stock Price Biodexa Pharmaceuticals PLC|BDRX - Average Forecast Price
- company stock capitalization data:
Market Valuation BDRX|BDRX - Business Value
- business book valuation details:
Book Value per Share Biodexa Pharmaceuticals|BDRX - Book Capitalization|Market Cap to Net Assets Ratio biodexapharma.com|BDRX - Aggregate Asset Value
- company total debt and liquidity indicators:
Debt to Equity Biodexa Pharmaceuticals|BDRX - Long-Term Liabilities to Equity|Short-Term Debt to Capital Biodexa Pharmaceuticals PLC|BDRX - Aggregate Debt Obligations|Debts to Book Capitalization BDRX|BDRX - Company Long-Term Debts|Company Short-Term Debt Biodexa Pharmaceuticals|Quick Liquidity biodexapharma.com
- financial results and valuation multiples details:
BDRX - Net Income|Projected Future Earnings Biodexa Pharmaceuticals|BDRX - P/E Multiple|Forward P/E Multiple Biodexa Pharmaceuticals PLC|BDRX - Price/Earnings to Growth Multiple|EV/EBITDA Multiple BDRX|BDRX - Profit before interest, taxes and amortization|Net earnings per share for the last 12 months Biodexa Pharmaceuticals|BDRX - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months biodexapharma.com|BDRX - Net earnings per one share growth for the current year|Earnings growth forecast for next year Biodexa Pharmaceuticals
- total revenue and sales volume data:
BDRX - Company Gross Revenue|Projected Sales Volume Biodexa Pharmaceuticals PLC|BDRX - Market Cap to Revenue|Forward P/S Multiple BDRX
Summary company analysis:Biodexa Pharma BDRX
Original product of biodexapharma.com

For Biodexa Pharmaceuticals (BDRX), which is developing innovative local therapy methods for brain tumors, the forward P/S history reflects the market valuation of its proprietary drug delivery technologies' potential. This indicator is calculated as the ratio of current market capitalization to projected revenue, allowing investors to assess the extent of expectations priced in and determine the risk of overpaying for the issuer's future commercial success.

Competitors of Biodexa Pharmaceuticals

Forward P/S Multiple CVS (CVS Health)|McKesson Corp (MCK) - Market Cap to Future Revenue Ratio|COR: Forward Price-to-Revenue Multiple|CAH (Cardinal Health Group) - Market Cap to Projected Revenue|HSIC: Forward P/S Multiple|prestigebrands.com (PBH) - Forward P/S Multiple|Forward Price-to-Revenue Multiple WGRX|YI: Forward Price to Sales|Price-to-Projected Revenue Ratio China Jo-Jo Drugstores Inc. (RDGT)|UPC: Future Price to Revenue|Forward P/S Multiple HKPD (Hong Kong Pharma Digital Limited)|Forward Price to Sales BIMI|Jiuzhou 360 - Forward P/S Multiple|WBA - Forward P/S Multiple